[go: up one dir, main page]

GB202203627D0 - Agents for treating complement-related disorders - Google Patents

Agents for treating complement-related disorders

Info

Publication number
GB202203627D0
GB202203627D0 GBGB2203627.1A GB202203627A GB202203627D0 GB 202203627 D0 GB202203627 D0 GB 202203627D0 GB 202203627 A GB202203627 A GB 202203627A GB 202203627 D0 GB202203627 D0 GB 202203627D0
Authority
GB
United Kingdom
Prior art keywords
agents
related disorders
treating complement
complement
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2203627.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Complement Therapeutics Ltd
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Priority to GBGB2203627.1A priority Critical patent/GB202203627D0/en
Publication of GB202203627D0 publication Critical patent/GB202203627D0/en
Priority to PCT/EP2023/056794 priority patent/WO2023175099A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2203627.1A 2022-03-16 2022-03-16 Agents for treating complement-related disorders Ceased GB202203627D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2203627.1A GB202203627D0 (en) 2022-03-16 2022-03-16 Agents for treating complement-related disorders
PCT/EP2023/056794 WO2023175099A1 (en) 2022-03-16 2023-03-16 Agents for treating complement-related disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2203627.1A GB202203627D0 (en) 2022-03-16 2022-03-16 Agents for treating complement-related disorders

Publications (1)

Publication Number Publication Date
GB202203627D0 true GB202203627D0 (en) 2022-04-27

Family

ID=81255000

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2203627.1A Ceased GB202203627D0 (en) 2022-03-16 2022-03-16 Agents for treating complement-related disorders

Country Status (2)

Country Link
GB (1) GB202203627D0 (en)
WO (1) WO2023175099A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100909681B1 (en) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Small RNA molecules that mediate JR interference
WO2008048675A2 (en) 2006-10-20 2008-04-24 Celldex Therapeutics, Inc. Treatment for age-related macular degeneration and other diseases of the eye
CA2704447A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
WO2013082563A1 (en) 2011-12-01 2013-06-06 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
US20150157675A1 (en) 2012-04-02 2015-06-11 Sung Kyun Biotech Co., Ltd. Composition comprising eupatorium spp. extract as active ingredient for preventing and treating obesity and metabolic bone disease
BR112014030677A2 (en) 2012-06-08 2022-07-19 Shire Human Genetic Therapies pulmonary distribution of mrna to non-pulmonary target cells
JP7068203B2 (en) 2016-06-28 2022-05-16 ウニベルジテート ウルム Complement inhibitors and their use
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3791180A1 (en) 2018-05-10 2021-03-17 The University Of Manchester Methods for assessing macular degeneration
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
GB202006789D0 (en) * 2020-05-07 2020-06-24 Univ Manchester Detection of complement proteins
WO2022058447A1 (en) 2020-09-16 2022-03-24 The University Of Manchester Complementome assay

Also Published As

Publication number Publication date
WO2023175099A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
IL289173A (en) Compositions and methods for treating cns disorders
IL294594A (en) Methods for treating pemphigus disorders
IL289172A (en) Compositions and methods for treating cns disorders
IL296215B1 (en) Purine compounds for treating disorders
IL310975A (en) Lou064 for treating multiple sclerosis
IL307607A (en) Tetracyclic compounds for treating brain disorders
IL292186A (en) Compositions and methods for treating blood disorders
GB202203627D0 (en) Agents for treating complement-related disorders
GB202314527D0 (en) New treatment for pain
IL317947A (en) Methods for treating complement-mediated diseases
IL288234A (en) Compounds for the treatment of neuromuscular disorders
CA3244720A1 (en) Agents for treating disorders involving ryanodine receptors
IL290319A (en) Compound for combination treatment
IL290770A (en) Compounds and methods for treating oxalate-related diseases
HUE064901T2 (en) Treatment system for treating workpieces
PL3733489T3 (en) Treatment system for treating workpieces
IL308424A (en) Use of pelabresib for treating anemias
IL291476A (en) Pharmacological composition for treating proctological diseases (variants)
GB202109675D0 (en) Treatment for tyrosine degradation-associated disorders
IL289018A (en) Methods for treating neurodegenerative disorders
GB202116350D0 (en) Agents for treating senescence-associated diseases or disorders
GB202002038D0 (en) Compounds for treating bone disorders
GB202007652D0 (en) Compounds for treating covid-19
HK40100817A (en) Agents for treating disorders involving ryanodine receptors
GB202308670D0 (en) New formulations for treating opioid use disorder

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: COMPLEMENT THERAPEUTICS LIMITED

Free format text: FORMER OWNER: THE UNIVERSITY OF MANCHESTER,

AT Applications terminated before publication under section 16(1)